Arcus Biosciences (RCUS) Return on Capital Employed (2018 - 2026)
Arcus Biosciences (RCUS) posted quarterly Return on Capital Employed of 46.33% for Q1 2026, down 198.0% year-over-year from 47.28% in Q1 2025, and up 0.91% quarter-over-quarter from 46.76% in Q4 2025.
Arcus Biosciences (RCUS) Return on Capital Employed (2018 - 2026) Analysis & Trends
Arcus Biosciences' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.33% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 198.0% year-over-year to 46.33%; the TTM figure through Mar 2026 stood at 46.33% (down 198.0% YoY), while the FY2025 annual figure was 42.26%, down 545.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 46.33%, up from 46.76% in the prior quarter.
- The five-year high for Return on Capital Employed was 5.96% in Q3 2022, with the low at 47.5% in Q3 2025.
- The 5-year median for Return on Capital Employed is 30.72% (2024), against an average of 27.64%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed soared 4436 bps in 2022, then slumped 3809 bps in 2023.
- Arcus Biosciences' Return on Capital Employed stood at 24.27% in 2022, then plunged by 46 bps to 35.45% in 2023, then grew by 7 bps to 33.03% in 2024, then tumbled by 42 bps to 46.76% in 2025, then gained by 1 bps to 46.33% in 2026.
- Business Quant data shows RCUS's Return on Capital Employed at 46.33% in Q1 2026, 46.76% in Q4 2025, and 47.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -63.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.74% |
| Mar 31, 2026 | -46.33% |
| Dec 31, 2025 | -46.76% |
| Sep 30, 2025 | -47.50% |
| Jun 30, 2025 | -36.44% |
| Mar 31, 2025 | -44.35% |
| Dec 31, 2024 | -33.03% |
| Sep 30, 2024 | -30.72% |
| Jun 30, 2024 | -27.88% |
| Mar 31, 2024 | -27.18% |
| Dec 31, 2023 | -35.45% |
| Sep 30, 2023 | -32.12% |
| Jun 30, 2023 | -29.61% |
| Mar 31, 2023 | -23.49% |
| Dec 31, 2022 | -24.27% |
| Sep 30, 2022 | 5.96% |
| Jun 30, 2022 | 4.97% |
| Mar 31, 2022 | 4.25% |
| Dec 31, 2021 | 4.46% |
| Sep 30, 2021 | -38.39% |